NASDAQ: $ABOS
NEWTON, Mass., Oct. 30, 2026 October 30, 2026 (GLOBE NEWSWIRE) — Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics that target…
Source: Read More